IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, it has been suggested that IFN therapy could reduce levels of pro-angiogenic vascular epidermal growth factor (VEGF), which is a biomarker used for CML severity (54, 55).